Analysis of myositis autoantibodies in Chinese patients with cancer-associated myositis
Open Access
- 1 August 2020
- journal article
- research article
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 34 (8), e23307
- https://doi.org/10.1002/jcla.23307
Abstract
Background Cancer-associated myositis (CAM) has poor prognosis and causes higher mortality. In general, myositis-specific autoantibodies (MSAs) and myositis-associated autoantibodies (MAAs) have been shown to be useful biomarkers for its diagnosis. Methods In the present study, focus was given in assessing the presence, prevalence, and diagnostic values of myositis autoantibodies in Chinese patients diagnosed with CAM. The sera collected from 49 CAM patients, 108 dermatomyositis/polymyositis (DM/PM) patients without cancer, 105 disease controls, and 60 healthy controls were detected for the presence of 16 autoantigens (Jo-1, OJ, EJ, PL-7, PL-12, MDA5, TIF1 gamma, Mi-2 alpha, Mi-2 beta, SAE1, NXP2, SRP, Ku, PM-Scl75, PM-Scl100, and Ro-52) using a commercial Euroline assay. Results The frequency of anti-TIF1 gamma was significantly higher in CAM patients than in DM/PM patients without cancer (46.9% vs 14.8%, P < .001). Importantly, the sensitivity and specificity for this MSA were 46.9% and 85.2%, respectively. These helped to differentiate CAM patients from DM/PM patients without cancer. However, there was no difference in other MSAs and MAAs between CAM and DM/PM patients without cancer. Conclusion The present study indicates that anti-TIF1 gamma levels can serve as important biomarkers for CAM diagnosis and help in distinguishing between CAM and DM/PM patients without cancer.Funding Information
- The CAMS Initiative for Innovative Medicine (2017-I2M-3-001, 2017-I2M-B&R-01)
- National Key Research and Development Program of China (2016YFC0903900)
- Research Special Fund for Public Welfare Industry of Health (201202004)
- National Natural Science Foundation of China grants (81671618, 81871302, 81501413, 81471615)
- Capital Health Research and Development of Special Fund (2014-1-4011)
This publication has 46 references indexed in Scilit:
- Tif1γ Suppresses Murine Pancreatic Tumoral Transformation by a Smad4-Independent PathwayThe American Journal of Pathology, 2012
- The TIF1α-related TRIM cofactors couple chromatin modifications to transcriptional regulation, signaling and tumor suppressionTranscription, 2011
- Transcription intermediary factor 1γ is a tumor suppressor in mouse and human chronic myelomonocytic leukemiaJCI Insight, 2011
- Antagonistic regulation of EMT by TIF1γ and Smad4 in mammary epithelial cellsEMBO Reports, 2011
- Association of overexpression of TIF1γ with colorectal carcinogenesis and advanced colorectal adenocarcinomaWorld Journal of Gastroenterology, 2011
- Myositis autoantibodies in Korean patients with inflammatory myositis: Anti-140-kDa polypeptide antibody is primarily associated with rapidly progressive interstitial lung disease independent of clinically amyopathic dermatomyositisBMC Musculoskeletal Disorders, 2010
- Polymyositis, dermatomyositis and malignancy: A further intriguing linkAutoimmunity Reviews, 2010
- The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositisAnnals Of The Rheumatic Diseases, 2007
- Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus GroupAnnals Of The Rheumatic Diseases, 2002
- The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritisArthritis & Rheumatism, 1988